

Ship Meds to:  Patient's Home  Prescriber's Office

|                               |   |      |
|-------------------------------|---|------|
| <b>Prescriber Information</b> |   |      |
| Prescriber Name:              | <input type="radio"/> MD <input type="radio"/> DO <input type="radio"/> NP <input type="radio"/> PA |      |
| Office Contact:               | NPI:  |      |
| Address:                      | Practice Name / Collaborating MD:   |      |
| State:                        | City:   |      |
| Zip:                          | Phone:  | Fax: |

|   |                       |                |  |   |         |   |  |
|---|-----------------------|----------------|--|---|---------|---|--|
| <b>Patient Information   PLEASE SEND COPY OF INSURANCE CARD</b> |                       |                |  |   |         |   |  |
| Patient's Name:   | Last 4 Digits of SS#: | DOB: / /       | Sex: <input type="radio"/> M <input type="radio"/> F | Weight:   | Height: | Diabetic: <input type="radio"/> Y <input type="radio"/> N |  |
| Address:  | City:                 | State:         | Zip:   | Allergies:  |         |   |  |
| Home Phone:   | Work Or Cell:         | HIPAA Contact: | Emergency #:   | Interpreter Needed? <input type="radio"/> Y <input type="radio"/> N |         |   |  |

|                              |                   |          |      |
|------------------------------|-------------------|----------|------|
| <b>Insurance Information</b> |                   |          |      |
| Primary Insurance:           | Policy ID:        | Group #: |      |
| Policyholder Name:           | Policyholder DOB: | BIN:     | PCN: |

|   |   |  |   |  |                 |  |  |
|---|---|--|---|--|-----------------|--|--|
| <b>Clinical Information   PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES AND LAB VALUES</b> |   |  |   |  |                 |  |  |
| ICD-10/Diagnosis Code:  | <input type="radio"/> Psoriasis Vulgaris (L40.0) <input type="radio"/> Other Psoriasis (L40.8) <input type="radio"/> Psoriasis unspecified (L40.9) <input type="radio"/> Psoriatic Arthritis (L40.5) <input type="radio"/> Hidradenitis Suppurativa (L73.2) <input type="radio"/> Chronic Urticaria (L50.8) |  |   |  |                 |  |  |
| <input type="radio"/> Atopic Dermatitis (L20.9)   | TB/PDD Test Given? <input type="radio"/> Y <input type="radio"/> N  | Date of Neg. Test: / /   | HBV Positive? <input type="radio"/> Y <input type="radio"/> N | If yes, patient currently treated? <input type="radio"/> Y <input type="radio"/> N |                 |  |  |
| Prior Treatment? <input type="radio"/> Y <input type="radio"/> N (Provide Information Below)  | BSA affected (%):   | Affected Areas: <input type="radio"/> Palms <input type="radio"/> Soles <input type="radio"/> Head <input type="radio"/> Neck <input type="radio"/> Genitalia <input type="radio"/> Other: |   |  |                 |  |  |
| Prior Therapy   | Reason for Discontinuation of Therapy   |  |   | Approx Start Date  | Approx End Date |  |  |
| Comorbidities:  | Concomitant Medications:  |  |   | Allergies: <input type="radio"/> NKDA <input type="radio"/> Other:                 |                 |  |  |

| <b>Prescription Information</b>  |   |  |            |
|--|---|--|------------|
| Medication   | Quantity/Dose   | Sig  | Refills    |
| <input type="radio"/> <b>HUMIRA®</b><br>(Plaque Psoriasis)<br><input type="radio"/> Pens <input type="radio"/> PFS   | <b>Pens Only:</b><br><input type="radio"/> Citrate-Free Starter Kit (1x80mg/0.8ml, 2x40mg/0.4ml)                                | <input type="radio"/> <b>Starter Dose:</b> Inject 80 mg SQ Day 1, then 40mg on day 8, then 1 pen every 2 weeks   | No Refills |
|  | <input type="radio"/> Citrate Free: 1 carton (2x40mg/0.4ml)   | <input type="radio"/> <b>Maintenance Dose:</b> Inject 40 mg SQ every 2 weeks   |            |
| <input type="radio"/> <b>HUMIRA®</b><br>(Hidradenitis Suppurativa)<br><input type="radio"/> Pens <input type="radio"/> PFS                                       | <b>Pens Only:</b><br><input type="radio"/> Citrate-Free Starter Kit (3x80mg/0.8ml)  | <b>Starter Dose:</b><br><input type="radio"/> <b>Adolescents weighing 30-59kg:</b> Inject 80mg SQ on day 1, 40mg on day 8 and 40mg on day 22<br><input type="radio"/> <b>Adolescents weighing ≥ 60kg and adults:</b> Inject 160mg SQ day 1 (or 80mg SQ on day 1 and day 2); then 80mg on day 15; then begin maintenance dosing on day 29 | No Refills |
|  | <b>Citrate Free</b><br><input type="radio"/> 2 cartons (4x40mg/0.4ml)<br><input type="radio"/> 1 carton (2x80mg/0.8ml) PEN ONLY | <b>Maintenance Dose:</b><br><input type="radio"/> <b>Adolescents weighing 30-59kg:</b><br><input type="radio"/> Inject 40mg SQ every other week<br><input type="radio"/> <b>Adolescents weighing ≥ 60kg and adults:</b><br><input type="radio"/> Inject 40mg SQ every week<br><input type="radio"/> Inject 80mg SQ every other week      |            |
| <input type="radio"/> <b>ILUMYA™</b>   | <input type="radio"/> 1 carton (1x100mg/mL PFS)   | <input type="radio"/> <b>Starter Dose:</b> Inject 100mg SQ at week 0. Start maintenance dose at week 4.  | No Refills |
|  |   | <input type="radio"/> <b>Maintenance Dose:</b> Inject 100mg SQ every 12 weeks  |            |
| <input type="radio"/> <b>ODOMZO®</b><br><input type="radio"/> Capsule  | <input type="radio"/> 200 mg capsule (30 capsules)  | <input type="radio"/> Take 1 capsule (200 mg) by mouth once daily on an empty stomach, at least 1 hour before or 2 hours after a meal  |            |
| <input type="radio"/> <b>ORENCIA®</b><br><input type="radio"/> Clickject® <input type="radio"/> PFS  | <input type="radio"/> 1 carton (4x125mg/ml)   | <input type="radio"/> <b>Maintenance Dose:</b> Inject 125 mg SQ once every week  |            |
| <input type="radio"/> <b>OTEZLA®</b><br><input type="radio"/> Tablet   | <input type="radio"/> 30 mg tablet (55 tabs for 28 Day Starter Pack)  | <input type="radio"/> <b>Starter Dose:</b> Take as directed per package instructions   | No Refills |
|  | <input type="radio"/> 30 mg tablet (60 tablets)   | <input type="radio"/> <b>Maintenance Dose:</b> Take 1 tablet by mouth twice daily  |            |
| <input type="radio"/> <b>SILIQ®</b><br><input type="radio"/> PFS<br><small>*Product is limited to certified prescribers enrolled in Siliq REMS</small>           | <input type="radio"/> 2 cartons (4x210mg/1.5mL)   | <input type="radio"/> <b>Starter Dose:</b> Inject 210 mg SQ at weeks 0, 1, and 2 and then every 2 weeks thereafter   | No Refills |
|  | <input type="radio"/> 1 carton (2x210mg/1.5mL)  | <input type="radio"/> <b>Maintenance Dose:</b> Inject 210 mg SQ once every 2 weeks   |            |
| <input type="radio"/> <b>SIMPONI®</b><br><input type="radio"/> SmartJect® <input type="radio"/> PFS  | <input type="radio"/> 1 carton (1x50mg/0.5ml)   | <input type="radio"/> Inject 50 mg SQ once a month   |            |
| <input type="radio"/> <b>SKYRIZI™</b><br><input type="radio"/> PFS<br>Patient eligible for self-injection?<br><input type="radio"/> Yes <input type="radio"/> No | <input type="radio"/> 2 cartons (2x75mg/0.83ml)   | <input type="radio"/> <b>Starter Dose:</b> Inject 150mg (2 syringes) SQ at weeks 0 and 4   |            |
|  | <input type="radio"/> 1 carton (2x75mg/0.83ml)  | <input type="radio"/> <b>Maintenance Dose:</b> Inject 150mg (2 syringes) SQ every 12 weeks   |            |

|   |   |   |
|---|---|---|
| <b>Injection Training</b>                                 |   |   |
| <input type="radio"/> Patient received injection training | <input type="radio"/> Prescriber's office to provide injection training | <input type="radio"/> Meijer to coordinate injection training |

By signing this form and utilizing our services, you are authorizing Meijer and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

|                       |      |                       |      |
|-----------------------|------|-----------------------|------|
| Prescriber Signature: | Date | Prescriber Signature: | Date |
|-----------------------|------|-----------------------|------|

Substitution Permitted

Dispense as Written